Novo Nordisk A/S ADR buy Morgan Stanley
Start price
23.01.24
/
50%
€95.40
Target price
23.01.25
€110.32
Performance (%)
-18.03%
End price
24.01.25
€78.20
Summary
This prediction ended on 24.01.25 with a price of €78.20. The price of Novo Nordisk A/S ADR has decreased during the runtime of the prediction. Compared to the start price this resulted in a performance of -18.03%. Morgan_Stanley has a follow-up prediction for Novo Nordisk A/S ADR, but this time predicts that Novo Nordisk A/S ADR is a Sell. Dividends of €1.08 are taken into consideration when calculating the performance. Morgan_Stanley has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y |
|---|---|---|---|
| Novo Nordisk A/S ADR | 6.569% | 6.569% | -47.733% |
| iShares Core DAX® | 0.224% | 2.031% | 21.399% |
| iShares Nasdaq 100 | 0.371% | -0.955% | 5.637% |
| iShares Nikkei 225® | 0.972% | -0.953% | 13.432% |
| iShares S&P 500 | 0.417% | -0.622% | 3.310% |
Comments by Morgan_Stanley for this prediction
In the thread Novo Nordisk A/S ADR diskutieren
Novo Nordisk A/S (NYSE: NVO) is now covered by analysts at Morgan Stanley. They set an "overweight" rating and a $120.00 price target on the stock.
Ratings data for NVO provided by MarketBeat
In the thread Trading Novo Nordisk A/S ADR
Die von Morgan_Stanley gewählte maximale Laufzeit wurde überschritten
Current prediction by Morgan_Stanley for Novo Nordisk A/S ADR
Novo Nordisk A/S ADR
Start price
Target price
Perf. (%)
€45.95
29.09.25
29.09.25
€40.10
29.09.26
29.09.26
-4.68%
23.12.25
23.12.25
